

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Rhonan Ford et al. Art Unit : 1625  
Serial No. : 10/566,320 Examiner : Nizal S. Chandrakumar  
Filed : January 26, 2006 Conf. No. : 3505  
Title : QUINOLINE DERIVATES AND THEIR USE IN THERAPY

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-490US1 / 101140-1P US.

Respectfully submitted,

Date: April 25, 2008

/John T. Kendall/

John T. Kendall, Ph.D.  
Reg. No. 50,680

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21908206.doc

**CERTIFICATE OF MAILING BY EFS-WEB FILING**

I hereby certify that this paper was filed with the Patent and Trademark Office using the EFS-WEB system on this date: April 25, 2008

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 06275-490US1	Application No. 10/566,320
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rhonan Ford et al.			
		Filing Date January 26, 2006		Group Art Unit 1625	

<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/N.C./	AA	3,464,998	09/02/1969	Krimmel			
	AB	3,471,491	10/07/1969	Venkatachala et al.			
	AC	4,751,292	06/14/1988	Fox			
	AD	6,949,539	09/27/2005	Alcaraz et al.			
	AE	7,129,246	10/31/2006	Alcaraz et al.			
/N.C./	AF	US2004/0236109	11/25/2004	Van Straten et al.			

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes      No
/N.C./	AG	BE 650919 A	07/23/1964	Belgium			Abstract
	AH	DE 1943404 A	12/17/1970	Germany			Abstract
	AI	EP 0002065 A1	05/30/1979	Europe			
	AJ	EP 0867436 A1	09/30/1998	Europe			
	AK	WO 95/04720	02/16/1995	WIPO			
	AL	WO 99/26927	06/03/1999	WIPO			
	AM	WO 99/29660	06/17/1999	WIPO			
	AN	WO 99/29661	06/17/1999	WIPO			
	AO	WO 00/61569	10/19/2000	WIPO			
	AP	WO 00/73283	12/07/2000	WIPO			
	AQ	WO 2001/037826	05/31/2001	WIPO			Abstract
	AR	WO 01/94338	12/13/2001	WIPO			
	AS	WO 03/042190	05/22/2003	WIPO			
	AT	WO 03/045313	06/05/2003	WIPO			
/N.C./	AU	WO 2006/059945	06/08/2006	WIPO			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>							
Examiner Initial	Desig. ID	Document					
/N.C./	AV	Accession No. 2003:42109, CAS Registry No. 487064-48-2					

Examiner Signature <i>/Nizal Chandrakumar/</i>	Date Considered 05/15/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-490US1	Application No. 10/566,320
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rhonan Ford et al.		
		Filing Date January 26, 2006	Group Art Unit 1625	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/N.C./	AW	Agosta et al., "Preparation of 3-Hydroxycyclohexaneacetonitriles", <i>J. Org. Chem.</i> 46:4880-4885 (1981)	
	AX	Alcaraz et al., "Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155	
	AY	Alcaraz et al., "Novel P2X7 Receptor Antagonists" <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4043-4046 (2003)	
	AZ	Baxter et al., "Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4047-4050 (2003)	
	AAA	Bourrie et al., "SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties," <i>Eur. J. of Pharm.</i> , 456:123-131 (2002)	
	ABB	Casy et al., "Synthesis and Pharmacological Evaluation of Some $\beta,\beta$ -Disubstituted Analogs of Acetylcholine", <i>J. Med. Chem.</i> 15(6):642-646 (1972)	
	ACC	Costakis et al., "Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles", <i>Journal of Medicinal Chemistry</i> 14(12):1222-1223 (1971)	
	ADD	Ferrari et al., "Extracellular ATP Triggers IL-1 $\beta$ Release by Activating the Purinergic P2Z Receptor of Human Macrophages", <i>J. Immunol.</i> 159:1451-1458 (1997)	
	AEE	Ferrari et al., "Purinergic Modulation of Interleukin-1 $\beta$ Release from Microglial Cells Stimulated with Bacterial Endotoxin", <i>J. Exp. Med.</i> 185(3):579-582 (1997)	
	AFF	Fulop et al., "A Versatile Method for the Synthesis of <i>cis</i> -2-aminomethylcyclanols", <i>Synthetic Communications</i> 28(12):2303-2309 (1998)	
	AGG	Henderson et al., "Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist", <i>Cytokine</i> 3(3):246-249 (1991)	
	AHH	Ho et al., "Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[ <i>ij</i> ] quinoline as a VLA-4 Antagonist", <i>J. Org. Chem.</i> 65:6743-6748, page 6745, scheme 5, (27) (2000)	
	AII	Kadota et al., "Significance of IL-1 $\beta$ and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)", <i>Clin Exp. Immunol.</i> 103:461-466 (1996)	
	AJJ	Khurana et al., "Clinical aspects of rheumatoid arthritis", <i>Pathophysiology</i> , Volume 12, Issue 3, Abstract (2005)	
	AKK	Kirkham, "Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis", <i>Annals of the Rheumatic Diseases</i> , 50:395-400 (1991)	
	ALL	Leonard et al., "Small Charged Rings. II. The Synthesis of Aziridinium Salts", <i>J. Am. Chem. Soc.</i> 84:4806-4813 (1962)	
	AMM	Li et al., "Should atherosclerosis be considered a cancer of the vascular wall?" <i>Medical Hypotheses</i> , 64:694-698 (2005)	
	ANN	Mackenzie et al., "Could rheumatoid arthritis have an infectious aetiology?" <i>Drug Discovery Today: Disease Mechanism</i> , Volume 2, Issue 3, Abstract (2005)	
	AOO	Miginiac et al., "Activation of Zinc by Trimethylchlorosilane: An Improved Procedure for the Preparation of $\beta$ -Hydroxy Esters from Ethyl Bromoacetate and Aldehydes or Ketones (Reformatsky Reaction)", <i>J. Org. Chem.</i> 52:4796-4798 (1987)	
/N.C./	APP	Otterness et al., "Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions", <i>Agent Act</i> 39 (Suppl):109-120 (1993)	

Examiner Signature /Nizal Chandrakumar/	Date Considered 05/15/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-490US1	Application No. 10/566,320
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rhonan Ford et al.		
		Filing Date January 26, 2006	Group Art Unit 1625	

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
/N.C./	AQQ	Richards et al., "Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy," <i>Eur. J. of Medic. Chem.</i> , 41:950-969 (2006)
	ARR	Sakito et al., "Interleukin 1 $\beta$ , Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy", <i>Respiration</i> 63:42-48 (1996)
	ASS	STN International, File REGISTRY, see RN 405068-97-5, 405070-41-9, 405076-22-4, 14 April 2002
	ATT	STN International, File REGISTRY, see RN 445032-09-7, 30 August 2002
	AUU	STN International, File CHEMCATS, Accession no. 2001:48444, 14 May 2001, NS18552, 2-Quinolinecarboxamide, N-(tricycle[3.3.1.13,7]dec-1-ylmethyl), CAS Registry No. 313688-07-2
	AVV	STN International, File REGISTRY, see RN 401622-10-4, 24 March 2002
	AWW	STN International, File REGISTRY, Registry Copyright 14 July 2006 ACS on STN RN: 892733-99-2, 1 page.
	AXX	STN International, File REGISTRY, Registry Copyright 08 August 2006 ACS on STN RN: 899526-58-0, 1 page.
	AYY	van den Berg, "Lessons from animal models of osteoarthritis, <i>Curr. Opin. Rheumatol.</i> , 13(5): 452-6 (2001)
	AZZ	Whitehead et al., "Diuretics. IV. 6-Chloro-3-substituted 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-Dioxides", <i>J. Org. Chem.</i> 26:2809-2813 (1961)
/N.C./	AAAA	Yu et al., "Inhibition of IL-1 Release from Human Monocytes and Suppression of Streptococcal Cell Wall and Adjuvant-induced Arthritis in Rats by an Extract of <i>Tripterygium wilfordii</i> Hook", <i>Gen. Pharmac.</i> 25(6):1115-1122 (1994)

Examiner Signature  /Nizal Chandrakumar/	Date Considered  /N.C./
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	